Report initial clinical trial data from the BEACON study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 28 Feb 2023
- Due
- 31 Dec 2024
- Delivered
- December 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Report initial data from multiple patients from one or both cohorts in 2024”
What we found
Evidence strength A What the grades mean
The company reported initial clinical data from the BEACON study in December 2024 at the American Society of Hematology Annual Meeting, fulfilling the commitment to report data within 2024.
-
A Beam Therapeutics Inc. 10-Q filed 2025-05-06
“In December 2024, we presented initial data from the BEACON trial at the 2024 American Society of Hematology Annual Meeting and Exposition, or ASH.” ✓ confirmed on the page
Market reaction: the shares moved -13.2% against the S&P 500 over the three sessions around the disclosure (5 May 2025 to 8 May 2025). What this measures
Checked 2 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 2 versions
-
Version 1 · original · stated 28 Feb 2023
Deadline 31 Dec 2024 (“in 2024”)
-
Version 2 · stated 10 May 2023
Deadline 31 Dec 2024 (“2024”) · wording expected
“The company continues to anticipate reporting initial data on multiple patients from the BEACON trial in 2024.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Initial clinical trial data
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Beam Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-BEAM-003230 · Corrections policy